Skip to main content
Premium Trial:

Request an Annual Quote

DoubleTwist Licenses Database to Merck

NEW YORK, Nov 29 – DoubleTwist has licensed its annotated human genome database package to Merck, DoubleTwist announced Wednesday.

The two-year license agreement covers the database and software for visualizing and interpreting the gene information, which Merck and seven affiliated companies plan to use in drug discovery. Merck had previously used DoubleTwist’s bioinformatics software.

“We are pleased to expand our existing relationship with a leading pharmaceutical company such as Merck," DoubleTwist CEO John Couch said in a statement." Prophecy provides a secure way for Merck to rapidly access and integrate our regularly updated annotated data within its in-house software systems."

The parties did not disclose additional terms of the agreement.

DoubleTwist’s other pharmaceutical customers for its bioinformatics software have included Eli Lilly, Isis Pharmaceuticals, and Bristol Myers Squibb. But Merck is the first major pharmaceutical company to publicly sign on for DoubleTwist’s new database.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.